We are live on ! Find out more
PHAR

Pharming Group
PHAR

4 hedge funds and large institutions have $630K invested in Pharming Group in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital invested

Capital invested by funds: $434K → $630K (+$196K)

0.08% more ownership

Funds ownership: 0.01% → 0.09% (+0.08%)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SBCM
Silverberg Bernstein Capital Management
New York
+$40.3K
2
EWA
EverSource Wealth Advisors
Alabama
+$28.9K

Top Sellers

Rank Fund Capital Flow
1
CCM
Coldstream Capital Management
Washington
-$887
Name Holding Trade Value Shares
Change 		Change in
Stake
SBCM
1
Silverberg Bernstein Capital Management
New York
$557K +$40.3K +4,150 +9%
EWA
2
EverSource Wealth Advisors
Alabama
$31.8K +$28.9K +2,979 New
Morgan Stanley
3
Morgan Stanley
New York
$31K – – –
NSG
4
Nalls Sherbakoff Group
Tennessee
$9.3K – – –
CCM
5
Coldstream Capital Management
Washington
– -$887 -106 Closed

PHAR Hedge Fund Activity: Q2 2025 in Review

4 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q2 2025, worth a combined $630K — up 45% from $434K a quarter earlier.

Fund positioning in PHAR was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Silverberg Bernstein Capital Management, adding an estimated $40.3K. The largest seller was Coldstream Capital Management, exiting entirely with an estimated $887 sold.

  • 4 institutional investors held Pharming Group (PHAR) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $630K of Pharming Group stock for Q2 2025, up 45% quarter-over-quarter.
  • 1 fund opened new Pharming Group positions in Q2 2025 and 1 closed out, a net change of 0 holders.
  • The largest Pharming Group buyer in Q2 2025 was Silverberg Bernstein Capital Management, an estimated $40.3K added.
  • The largest Pharming Group seller in Q2 2025 was Coldstream Capital Management, an estimated $887 sold.

Based on aggregated 13F filings for Q2 2025.